Evidence map›Paper›PMID 42233314›Full record

ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2026

Reduction in hippocampal cholinergic neurostimulating peptide enhances memory impairment in App

Yo Tsuda, Yuta Madokoro, Kengo Suzuki, Takuya Ooba, Toyohiro Sato, Yuto Uchida, Itsumi Nagai-Arakawa, Takashi Saito, Hideaki Hara, Hideki Hida and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Yo TsudaDepartment of Neurology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
Yuta MadokoroDepartment of Neurology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
Kengo SuzukiDepartment of Neurology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
Takuya OobaDepartment of Biofunctional Evaluation, Molecular Pharmacology, Gifu Pharmaceutical University, Gifu, Japan.
Toyohiro SatoDepartment of Neurology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
Yuto UchidaDepartment of Neurology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
Itsumi Nagai-ArakawaDepartment of Neurology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
Takashi SaitoDepartment of Neurocognitive Sciences, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
Hideaki HaraDepartment of Biofunctional Evaluation, Molecular Pharmacology, Gifu Pharmaceutical University, Gifu, Japan.
Hideki HidaDepartment of Neurophysiology and Brain Sciences, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
Noriyuki MatsukawaDepartment of Neurology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.

Funding

Daiichi-SankyoDainippon Sumitomo PharmaEisaiJapan Society for the Promotion of Science 23K14697Japan Society for the Promotion of Science 23K14698Japan Society for the Promotion of Science JPMXS0441500024Japan Society for the Promotion of Science KakenhiOtsuka Pharmaceutical
6 · The paper itself

Abstract

introductionWhether cholinergic activity in the septohippocampal network affects cognitive dysfunction via hippocampal cholinergic neurostimulating peptide (HCNP) in Alzheimer's pathogenesis remains unclear.

methodsAn Alzheimer's pathogenesis by mutation in amyloid-beta precursor protein gene (App

resultsReduced HCNP levels enhanced cognitive impairment, inhibiting theta power and LTP, although without accompanying pathological changes or inflammation. Decreased N-methyl-D-aspartate receptor subunit 2A (NR2A), choline acetyltransferase (ChAT), and Vesicular acetylcholine transporter (VAChT) levels were observed in the hippocampus and ChAT in the medial septal nucleus (MSN) of App DISCUSSION: Cholinergic dysfunction in HCNP-pp cKO mice exacerbates cognitive dysfunction in App

Indexed as

Alzheimer DiseaseAmyloid beta-Protein PrecursorHippocampusMemory DisordersNeuropeptidesAnimalsDisease Models, AnimalLong-Term PotentiationMaleMiceMice, KnockoutMice, TransgenicAmyloid beta-Protein Precursorhippocampal cholinergic neurostimulating peptideNeuropeptidesAlzheimer's diseaseAppNL‐G‐F knock‐incholinergic dysfunctionhippocampal cholinergic neurostimulating peptidehippocampal cholinergic neurostimulating peptide precursor protein

Identifiers

PMID42233314
PMCPMC13240342

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.